ZA200307794B - Modified cyclosporine which can be used as a pro-drug and use thereof. - Google Patents

Modified cyclosporine which can be used as a pro-drug and use thereof. Download PDF

Info

Publication number: ZA200307794B
Authority: ZA; South Africa
Prior art keywords: meleu; pro; ala; drug; val
Prior art date: 2001-04-20

Application number

ZA200307794A

Other languages

English (en)

Inventor

Roland Wenger

Arnaud Hamel

Manfred Mutter

Francis Hubler

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-20

Filing date

2003-10-06

Publication date

2004-07-19

2003-10-06 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

2004-07-19 Publication of ZA200307794B publication Critical patent/ZA200307794B/en

Links

239000000651 prodrug Substances 0.000 title claims description 61
229940002612 prodrug Drugs 0.000 title claims description 61
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title description 98
229940064638 modified cyclosporine Drugs 0.000 title 1
125000004122 cyclic group Chemical group 0.000 claims description 57
125000001424 substituent group Chemical group 0.000 claims description 41
150000001413 amino acids Chemical class 0.000 claims description 28
125000004432 carbon atom Chemical group C* 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 27
239000000126 substance Substances 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 25
238000011282 treatment Methods 0.000 claims description 23
125000000539 amino acid group Chemical group 0.000 claims description 19
238000000034 method Methods 0.000 claims description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
229940126601 medicinal product Drugs 0.000 claims description 16
125000002877 alkyl aryl group Chemical group 0.000 claims description 13
125000003710 aryl alkyl group Chemical group 0.000 claims description 13
206010023332 keratitis Diseases 0.000 claims description 13
230000001575 pathological effect Effects 0.000 claims description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
125000004404 heteroalkyl group Chemical group 0.000 claims description 9
125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 9
125000000623 heterocyclic group Chemical group 0.000 claims description 9
-1 alkylheterocyclic Chemical group 0.000 claims description 8
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 7
241001102832 Meseres Species 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
201000010666 keratoconjunctivitis Diseases 0.000 claims description 5
210000004400 mucous membrane Anatomy 0.000 claims description 5
210000000056 organ Anatomy 0.000 claims description 5
206010057380 Allergic keratitis Diseases 0.000 claims description 4
206010010741 Conjunctivitis Diseases 0.000 claims description 4
208000031886 HIV Infections Diseases 0.000 claims description 4
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 4
208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
206010052779 Transplant rejections Diseases 0.000 claims description 4
238000009098 adjuvant therapy Methods 0.000 claims description 4
239000003246 corticosteroid Substances 0.000 claims description 4
229960001334 corticosteroids Drugs 0.000 claims description 4
238000001914 filtration Methods 0.000 claims description 4
230000002197 limbic effect Effects 0.000 claims description 4
230000010076 replication Effects 0.000 claims description 4
208000025889 stromal keratitis Diseases 0.000 claims description 4
238000001356 surgical procedure Methods 0.000 claims description 4
210000001185 bone marrow Anatomy 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
210000002216 heart Anatomy 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
210000004185 liver Anatomy 0.000 claims description 3
210000004072 lung Anatomy 0.000 claims description 3
210000000496 pancreas Anatomy 0.000 claims description 3
230000002035 prolonged effect Effects 0.000 claims description 3
210000000813 small intestine Anatomy 0.000 claims description 3
230000004083 survival effect Effects 0.000 claims description 3
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
108010036949 Cyclosporine Proteins 0.000 description 78
229930105110 Cyclosporin A Natural products 0.000 description 76
229960001265 ciclosporin Drugs 0.000 description 76
239000000243 solution Substances 0.000 description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
229930182912 cyclosporin Natural products 0.000 description 33
238000002360 preparation method Methods 0.000 description 32
230000002829 reductive effect Effects 0.000 description 22
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
229940024606 amino acid Drugs 0.000 description 19
238000003756 stirring Methods 0.000 description 17
108010036941 Cyclosporins Proteins 0.000 description 13
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 11
239000012043 crude product Substances 0.000 description 11
239000012074 organic phase Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 9
230000000694 effects Effects 0.000 description 9
230000007017 scission Effects 0.000 description 9
239000002904 solvent Substances 0.000 description 9
239000006260 foam Substances 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
230000007794 irritation Effects 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
239000011734 sodium Substances 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
229910052786 argon Inorganic materials 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010010726 Conjunctival oedema Diseases 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
239000004473 Threonine Substances 0.000 description 5
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
125000001841 imino group Chemical group [H]N=* 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
229960002898 threonine Drugs 0.000 description 5
108090000371 Esterases Proteins 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
210000004087 cornea Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 3
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 description 3
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 3
231100000635 Draize test Toxicity 0.000 description 3
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000007385 chemical modification Methods 0.000 description 3
108010019248 cyclosporin C Proteins 0.000 description 3
108010019594 cyclosporin D Proteins 0.000 description 3
108010019249 cyclosporin G Proteins 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000009434 installation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
229920000724 poly(L-arginine) polymer Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000003381 solubilizing effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000003556 Dry Eye Syndromes Diseases 0.000 description 2
206010013774 Dry eye Diseases 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
239000007821 HATU Substances 0.000 description 2
206010047513 Vision blurred Diseases 0.000 description 2
WRYNUJYAXVDTCB-UHFFFAOYSA-M acetyloxymercury Chemical compound CC(=O)O[Hg] WRYNUJYAXVDTCB-UHFFFAOYSA-M 0.000 description 2
230000009471 action Effects 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
108010011110 polyarginine Proteins 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
229920002994 synthetic fiber Polymers 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000006257 total synthesis reaction Methods 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 description 1
QKAIIJHXZDNKMY-BYPYZUCNSA-N (2s)-4-hydroxy-2-(methylamino)butanoic acid Chemical group CN[C@H](C(O)=O)CCO QKAIIJHXZDNKMY-BYPYZUCNSA-N 0.000 description 1
LGVJIYCMHMKTPB-DMTCNVIQSA-N (2s,3r)-2-azaniumyl-3-hydroxypentanoate Chemical group CC[C@@H](O)[C@H](N)C(O)=O LGVJIYCMHMKTPB-DMTCNVIQSA-N 0.000 description 1
NGEWQZIDQIYUNV-SCSAIBSYSA-N (R)-2-hydroxy-3-methylbutyric acid Chemical group CC(C)[C@@H](O)C(O)=O NGEWQZIDQIYUNV-SCSAIBSYSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
NTNWOCRCBQPEKQ-UHFFFAOYSA-N 2-azaniumyl-5-[(n'-methylcarbamimidoyl)amino]pentanoate Chemical compound CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010011026 Corneal lesion Diseases 0.000 description 1
108010002156 Depsipeptides Proteins 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
208000005772 N syndrome Diseases 0.000 description 1
PQNASZJZHFPQLE-UHFFFAOYSA-N N(6)-methyllysine Chemical group CNCCCCC(N)C(O)=O PQNASZJZHFPQLE-UHFFFAOYSA-N 0.000 description 1
PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
239000010432 diamond Substances 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000002571 electroretinography Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000000544 hyperemic effect Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
125000000879 imine group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100001180 nonmyelotoxic Toxicity 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000011894 semi-preparative HPLC Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
231100000456 subacute toxicity Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Virology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200307794A 2001-04-20 2003-10-06 Modified cyclosporine which can be used as a pro-drug and use thereof. ZA200307794B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH7202001		2001-04-20

Publications (1)

Publication Number	Publication Date
ZA200307794B true ZA200307794B (en)	2004-07-19

Family

ID=4531478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200307794A ZA200307794B (en)	2001-04-20	2003-10-06	Modified cyclosporine which can be used as a pro-drug and use thereof.

Country Status (17)

Country	Link
US (1)	US6995139B2 (de)
EP (1)	EP1379547B1 (de)
JP (1)	JP4588979B2 (de)
KR (1)	KR100932859B1 (de)
CN (1)	CN1507451A (de)
AT (1)	ATE313557T1 (de)
AU (1)	AU2002245996B8 (de)
BR (1)	BR0208923A (de)
CA (1)	CA2444278C (de)
DE (1)	DE60208180T2 (de)
ES (1)	ES2256450T3 (de)
IL (1)	IL158385A0 (de)
MX (1)	MXPA03009586A (de)
RU (1)	RU2290196C2 (de)
UA (1)	UA75136C2 (de)
WO (1)	WO2002085928A2 (de)
ZA (1)	ZA200307794B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7354574B2 (en) *	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
US7083803B2 (en)	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
US7087237B2 (en)	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
CA2571710A1 (en)	2004-06-24	2006-11-02	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
EP1904056B1 (de)	2005-07-18	2009-04-29	Minu, L.L.C.	Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
US7696165B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7531572B2 (en)	2006-07-28	2009-05-12	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US8394763B2 (en)	2007-09-26	2013-03-12	Oregon Health & Science University	Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) *	2008-02-08	2009-08-13	Debiopharm Sa	Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
GB0912584D0 (en) *	2009-07-20	2009-08-26	Ucl Business Plc	Cyclosporin conjugates
RU2630690C9 (ru)	2010-12-15	2017-12-28	КонтраВир Фармасьютикалз, Инк.	МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ
AR090964A1 (es) *	2012-05-09	2014-12-17	Novartis Ag	Proceso para la elaboracion de undecapeptidos ciclicos
CN113388002A (zh) *	2021-06-10	2021-09-14	梯尔希（南京）药物研发有限公司	一种环孢菌素相关化合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4396542A (en) *	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
ATE43335T1 (de) *	1980-02-14	1989-06-15	Sandoz Ag	Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
US5169773A (en) *	1984-10-04	1992-12-08	Sandoz Ltd.	Monoclonal antibodies to cyclosporins
ATE43499T1 (de) *	1984-10-10	1989-06-15	Ile De France	Synergistische empfaengnisverhuetende mischung.
US4764503A (en) *	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
DK0484281T4 (da) *	1990-11-02	2001-02-05	Novartis Ag	Cyclosporiner
US6187547B1 (en) *	1993-09-08	2001-02-13	Novartis Ag	Assay kit
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
US6017879A (en) *	1998-04-03	2000-01-25	B.M.R.A. Corporation B.V.	Template associated NPY Y2-receptor agonists
DE69928938T2 (de)	1998-07-01	2006-08-17	Debiopharm S.A.	Neues cyclosporin mit verbesserter wirkung
US6204257B1 (en) *	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
DE60028936T2 (de) *	1999-02-05	2007-01-11	Debiopharm S.A.	Cyclosporin-derivate und verfahren zu deren herstellung
US6765019B1 (en) *	1999-05-06	2004-07-20	University Of Kentucky Research Foundation	Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
WO2001005819A1 (en) *	1999-07-15	2001-01-25	Kuhnil Pharm. Co., Ltd.	Novel water soluble-cyclosporine conjugated compounds
MXPA02001857A (es) *	1999-08-24	2003-07-14	Cellgate Inc	Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.

2002
- 2002-04-22 CA CA2444278A patent/CA2444278C/en not_active Expired - Fee Related
- 2002-04-22 UA UA20031110436A patent/UA75136C2/uk unknown
- 2002-04-22 JP JP2002583454A patent/JP4588979B2/ja not_active Expired - Fee Related
- 2002-04-22 MX MXPA03009586A patent/MXPA03009586A/es active IP Right Grant
- 2002-04-22 ES ES02713992T patent/ES2256450T3/es not_active Expired - Lifetime
- 2002-04-22 AT AT02713992T patent/ATE313557T1/de not_active IP Right Cessation
- 2002-04-22 WO PCT/CH2002/000222 patent/WO2002085928A2/fr active IP Right Grant
- 2002-04-22 BR BR0208923-8A patent/BR0208923A/pt active Search and Examination
- 2002-04-22 EP EP02713992A patent/EP1379547B1/de not_active Expired - Lifetime
- 2002-04-22 CN CNA028094050A patent/CN1507451A/zh active Pending
- 2002-04-22 AU AU2002245996A patent/AU2002245996B8/en not_active Ceased
- 2002-04-22 RU RU2003133742/15A patent/RU2290196C2/ru not_active IP Right Cessation
- 2002-04-22 IL IL15838502A patent/IL158385A0/xx not_active IP Right Cessation
- 2002-04-22 US US10/474,396 patent/US6995139B2/en not_active Expired - Fee Related
- 2002-04-22 DE DE60208180T patent/DE60208180T2/de not_active Expired - Lifetime
2003
- 2003-10-06 ZA ZA200307794A patent/ZA200307794B/en unknown
- 2003-10-17 KR KR1020037013666A patent/KR100932859B1/ko not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE60208180T2 (de)	2006-08-17
CA2444278C (en)	2011-11-22
KR100932859B1 (ko)	2009-12-23
EP1379547A2 (de)	2004-01-14
UA75136C2 (en)	2006-03-15
AU2002245996B2 (en)	2005-06-30
JP4588979B2 (ja)	2010-12-01
IL158385A0 (en)	2004-05-12
KR20030094357A (ko)	2003-12-11
RU2003133742A (ru)	2005-03-20
CA2444278A1 (en)	2002-10-31
AU2002245996B8 (en)	2005-07-14
US20040138108A1 (en)	2004-07-15
US6995139B2 (en)	2006-02-07
CN1507451A (zh)	2004-06-23
ES2256450T3 (es)	2006-07-16
ATE313557T1 (de)	2006-01-15
MXPA03009586A (es)	2004-05-24
EP1379547B1 (de)	2005-12-21
JP2004536051A (ja)	2004-12-02
RU2290196C2 (ru)	2006-12-27
DE60208180D1 (de)	2006-01-26
WO2002085928A2 (fr)	2002-10-31
BR0208923A (pt)	2004-04-27
WO2002085928A3 (fr)	2003-04-17

Publication	Publication Date	Title
EP1091975B1 (de)	2005-12-14	Neues cyclosporin mit verbesserter wirkung
AU2002245996B2 (en)	2005-06-30	Modified cyclosporine which can be used as a pro-drug and use thereof
US6809077B2 (en)	2004-10-26	Cyclosporin analogs for the treatment of autoimmune diseases
US6979671B2 (en)	2005-12-27	Cyclosporins for the treatment of immune disorders
US20030186855A1 (en)	2003-10-02	Cyclosporins for the treatment of immune disorders
US20040157768A1 (en)	2004-08-12	Cyclosporins for the treatment of immune disorders
JP2020189847A (ja)	2020-11-26	ペプチド及びペプチド関連化合物の高浸透性プロドラッグ組成物
MX2011001152A (es)	2011-06-09	Moleculas de analogo de ciclosporina no-inmunesupresoras.
JPH03218396A (ja)	1991-09-25	シクロスポリン誘導体
CA2763207A1 (en)	2010-12-02	Cyclosporin derivatives for treating inflammatory diseases and conditions
WO2001005818A1 (en)	2001-01-25	Novel water soluble-cyclosporin conjugated compounds
WO1993017039A1 (en)	1993-09-02	Iso-cyclosporin salts
WO2018001273A1 (zh)	2018-01-04	肽或其盐、其制备方法、及其制备预防和/或治疗肝损伤药物的用途
PL164131B1 (pl)	1994-06-30	Sposób wytwarzania nowej cyklosporyny